MCID: HYP014
MIFTS: 56

Hyperuricemia

Categories: Blood diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Hyperuricemia

MalaCards integrated aliases for Hyperuricemia:

Name: Hyperuricemia 12 77 56 45 15 17 74
Blood Urate Raized 12
Uricacidemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1920
MeSH 45 D033461
NCIt 51 C3961
SNOMED-CT 69 35885006
UMLS 74 C0740394

Summaries for Hyperuricemia

Disease Ontology : 12 An acquired metabolic disease that has material basis in an abnormally high level of uric acid in the blood.

MalaCards based summary : Hyperuricemia, also known as blood urate raized, is related to hyperuricemic nephropathy, familial juvenile, 1 and glycogen storage disease ia, and has symptoms including seizures, muscle weakness and fever. An important gene associated with Hyperuricemia is UMOD (Uromodulin), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics. The drugs Allopurinol and Furosemide have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and endothelial, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 77 Hyperuricemia is an abnormally high level of uric acid in the blood. In the pH conditions of body fluid,... more...

Related Diseases for Hyperuricemia

Diseases in the Hyperuricemia family:

Hereditary Hyperuricemia

Diseases related to Hyperuricemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 210)
# Related Disease Score Top Affiliating Genes
1 hyperuricemic nephropathy, familial juvenile, 1 32.7 HPRT1 SLC22A12 UMOD
2 glycogen storage disease ia 32.5 G6PC INS
3 gout 31.2 ABCG2 HPRT1 SLC17A1 SLC17A3 SLC22A12 SLC2A9
4 chronic kidney failure 30.3 APOB INS REN UMOD
5 nephrolithiasis, uric acid 30.1 HPRT1 XDH
6 arteries, anomalies of 29.9 APOB INS REN
7 nephrolithiasis 29.6 HPRT1 INS SLC22A12 SLC2A9 UMOD XDH
8 nonalcoholic steatohepatitis 29.5 GPT INS
9 hypertension, essential 29.4 ADRB3 APOB INS REN
10 cerebrovascular disease 29.2 APOB INS REN
11 vascular disease 29.2 APOB INS REN XDH
12 diabetes mellitus, noninsulin-dependent 29.1 ADRB3 APOB G6PC GPT INS
13 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 12.5
14 glomerulocystic kidney disease with hyperuricemia and isosthenuria 12.4
15 hereditary hyperuricemia 12.2
16 deafness hyperuricemia neurologic ataxia 12.1
17 lesch-nyhan syndrome 12.0
18 hyperuricemia, infantile, with abnormal behavior and normal hypoxanthine guanine phosphoribosyltransferase 12.0
19 nephropathy familial with hyperuricemia 12.0
20 hyperuricemic nephropathy, familial juvenile, 2 11.7
21 kelley-seegmiller syndrome 11.7
22 urate oxidase, pseudogene 11.3
23 fructose intolerance, hereditary 11.3
24 glycogen storage disease ib 11.1
25 autosomal dominant tubulointerstitial kidney disease 11.1
26 autosomal dominant tubulointerstitial kidney disease, ren-related 11.0
27 uric acid concentration, serum, quantitative trait locus 1 11.0
28 glycogen storage disease ic 11.0
29 osteodysplasia, familial, anderson type 11.0
30 phosphoribosylpyrophosphate synthetase superactivity 11.0
31 hyperuricemic nephropathy, familial juvenile, 4 11.0
32 familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis 11.0
33 kidney disease 10.6
34 arthritis 10.4
35 leukemia 10.4
36 heart disease 10.4
37 rere-related disorders 10.4
38 atrial fibrillation 10.3
39 diabetes mellitus 10.3
40 coronary heart disease 1 10.3
41 lymphoma 10.3
42 fatty liver disease 10.3
43 liver disease 10.3
44 nonalcoholic fatty liver disease 10.3
45 purine-pyrimidine metabolic disorder 10.3 HPRT1 XDH
46 adenine phosphoribosyltransferase deficiency 10.2 HPRT1 XDH
47 fanconi-bickel syndrome 10.2 G6PC INS
48 myocardial infarction 10.2
49 glycogen storage disease 10.2
50 hypouricemia, renal, 1 10.2 HPRT1 SLC22A12 SLC2A9

Graphical network of the top 20 diseases related to Hyperuricemia:



Diseases related to Hyperuricemia

Symptoms & Phenotypes for Hyperuricemia

UMLS symptoms related to Hyperuricemia:


seizures, muscle weakness, fever, polydipsia, dyspnea, edema, cachexia, vertigo, headache, syncope, cyanosis, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes

MGI Mouse Phenotypes related to Hyperuricemia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 ABCG2 ADRB3 G6PC HPRT1 INS PFKM
2 homeostasis/metabolism MP:0005376 10.03 ABCG2 ADRB3 APOB G6PC HPRT1 INS
3 growth/size/body region MP:0005378 10.02 ADRB3 APOB G6PC HPRT1 INS REN
4 adipose tissue MP:0005375 9.88 ABCG2 ADRB3 INS SLC2A9 UMOD XDH
5 immune system MP:0005387 9.81 ABCG2 APOB HPRT1 INS PFKM REN
6 liver/biliary system MP:0005370 9.43 ABCG2 APOB G6PC HPRT1 INS SLC2A9
7 renal/urinary system MP:0005367 9.28 ABCG2 G6PC HPRT1 INS REN SLC22A12

Drugs & Therapeutics for Hyperuricemia

Drugs for Hyperuricemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Allopurinol Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 315-30-0 2094
2
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
3
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
4
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
5
Rasburicase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134774-45-1
6
Febuxostat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 144060-53-7 134018
7
Probenecid Approved, Investigational Phase 4,Phase 2 57-66-9 4911
8
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
9
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 130881 158781
10
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
11
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
12
Naproxen Approved, Vet_approved Phase 4 22204-53-1 156391 1302
13
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
14
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
15
leucovorin Approved Phase 4 58-05-9 6006 143
16
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
17
Canagliflozin Approved Phase 4 842133-18-0
18
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
19
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
21
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
22
Uric Acid Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 69-93-2 1175
23
Cobalamin Experimental Phase 4 13408-78-1 6857388
24
Rosemary Experimental Phase 4
25 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
26 Anthocyanidin Phase 4,Not Applicable
27 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Free Radical Scavengers Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
29 Anti-Infective Agents Phase 4,Phase 3,Phase 1
30
Procyanidin Phase 4 4852-22-6 147299
31 Antiparasitic Agents Phase 4
32 Proanthocyanidin Phase 4
33 Antiprotozoal Agents Phase 4
34 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
36 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Not Applicable
37 diuretics Phase 4,Phase 3
38 Sodium Chloride Symporter Inhibitors Phase 4,Phase 3
39 Sodium Potassium Chloride Symporter Inhibitors Phase 4
40 Natriuretic Agents Phase 4,Phase 3
41 Hormones Phase 4,Phase 2,Phase 3
42 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
43 Hormone Antagonists Phase 4,Phase 2,Phase 3
44 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
46 glucocorticoids Phase 4,Phase 2,Phase 3
47 Insulin, Globin Zinc Phase 4,Phase 3,Not Applicable
48 insulin Phase 4,Phase 3,Not Applicable
49 Renal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
50 Angiotensin Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 165)
# Name Status NCT ID Phase Drugs
1 Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines Unknown status NCT02797028 Phase 4 Allopurinol
2 Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function Unknown status NCT01977430 Phase 4 Hydrochlorothiazide and furosemide
3 Prednisone for Heart Failure Patients With Hyperuricemia Completed NCT00919243 Phase 4 prednisone;allopurinol
4 Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4 Rasburicase
5 Zurig (Febuxostat) 40mg Efficacy and Safety Trial Completed NCT02600780 Phase 4 Febuxostat;Allopurinol
6 Rasburicase in Tumor Lysis Syndrome Completed NCT00302653 Phase 4 Rasburicase
7 Treatment of Hyperuricemia in Patients With Heart Failure Completed NCT00422318 Phase 4 Benzbromarone (drug)
8 Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome Completed NCT01654276 Phase 4 Febuxostat
9 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)
10 Allopurinol in Chronic Heart Failure Completed NCT00997542 Phase 4 Allopurinol;Placebo
11 Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers Completed NCT01907373 Phase 4 olmesartan medoxomil;olmesartan medoxomil+probenecid
12 Allopurinol Outcome Study Completed NCT01391325 Phase 4 Allopurinol
13 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
14 Fasturtec TLS Treatment / Prophylysis Completed NCT00651911 Phase 4 urate oxidase
15 Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels Completed NCT02060552 Phase 4 Diacerein;Colchicine;Febuxostat
16 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout Completed NCT02500641 Phase 4 Febuxostat 80/120mg/day;Allopurinol 100 up to 600mg/day;Colchicine;Naproxen;Omeprazole
17 Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients Recruiting NCT03200210 Phase 4 Febuxostat;Placebo
18 Effect of Hyperuricaemia on Chronic Renal Disease Recruiting NCT03425708 Phase 4 20mg Febuxostat;40mg Febuxostat
19 The Intervention of Multi-vitamin With Minerals to Hyperuricemia Recruiting NCT03218709 Phase 4
20 Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction Active, not recruiting NCT03534037 Phase 4 Febuxostat 40 mg;Benzbromarone 50mg
21 The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Active, not recruiting NCT02956278 Phase 4 Allopurinol
22 Pharmacogenetics of SGLT2 Inhibitors Active, not recruiting NCT02462421 Phase 4 Canagliflozin
23 The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) Enrolling by invitation NCT03336203 Phase 4 Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet
24 Allopurinol in Acute Coronary Syndrome Not yet recruiting NCT03745729 Phase 4 allopurinol sustained-release capsules;placebo capsules
25 the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia Terminated NCT02279342 Phase 4 Febuxostat
26 Long-term Prednisone Use for End-stage Heart Failure Unknown status NCT02282683 Phase 2, Phase 3 prednisone
27 The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients Unknown status NCT02563405 Phase 2, Phase 3 Doxazosin;Nifedipine
28 Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients Unknown status NCT02533648 Phase 3 2 capsules of allopurinol 150 mg daily for 3 month;2 capsules of lactose daily for 3 month
29 Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout Completed NCT03372200 Phase 3 FYU-981;Febuxostat
30 Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout Completed NCT03100318 Phase 3 FYU-981;Benzbromarone
31 Prednisone for Heart Failure Patients With Hyperuricemia Completed NCT02129764 Phase 2, Phase 3 Prednisone;Allopurinol
32 Study of FYU-981 in Hyperuricemia With or Without Gout Completed NCT03006445 Phase 3 FYU-981
33 Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia Completed NCT00921375 Phase 3 TULY
34 Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome Completed NCT00230178 Phase 3 Rasburicase (SR29142);Allopurinol
35 Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma Completed NCT00199043 Phase 3 Allopurinol;Rasburicase
36 Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout Completed NCT00325195 Phase 3
37 Efficacy and Safety of Oral Febuxostat in Participants With Gout Completed NCT00430248 Phase 3 Febuxostat;Febuxostat;Allopurinol
38 UAB Center of Research Translation (CORT) Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure Completed NCT02038179 Phase 2, Phase 3 Allopurinol;Placebo
39 Uric Acid and Hypertension in African Americans Completed NCT00241839 Phase 3 Allopurinol;Placebo;Chlorthalidone;Potassium chloride
40 Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout Completed NCT01356498 Phase 3
41 Molecular and Clinical Effects of Green Tea and Fermented Papaya Preparation on Diabetes and Cardiovascular Diseases Completed NCT01248143 Phase 2, Phase 3
42 Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients. Completed NCT02866214 Phase 2, Phase 3 Febuxostat;Placebo
43 Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Completed NCT00175019 Phase 3 Febuxostat;Febuxostat;Allopurinol
44 Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) Completed NCT01101035 Phase 3 Febuxostat;Allopurinol
45 BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada Completed NCT00272779 Phase 3 ATV;RTV;Tenofovi-Emtricitabine (TDF/FTC) tablet;LPV
46 Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer Completed NCT01234337 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo;Capecitabine
47 Rasburicase (Fasturtec) Registration Trial Terminated NCT00607152 Phase 3 Rasburicase;Allopurinol
48 Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout Unknown status NCT01519687 Phase 2 levotofisopam
49 A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product. Unknown status NCT00208000 Phase 2 Marine active
50 Hyperuricemia on Hypertension and Metabolic Syndrome Completed NCT01157936 Phase 2 Allopurinol

Search NIH Clinical Center for Hyperuricemia

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: hyperuricemia

Genetic Tests for Hyperuricemia

Anatomical Context for Hyperuricemia

MalaCards organs/tissues related to Hyperuricemia:

42
Kidney, Heart, Endothelial, Liver, Breast, Skeletal Muscle, Lung

Publications for Hyperuricemia

Articles related to Hyperuricemia:

(show top 50) (show all 1639)
# Title Authors Year
1
Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) progression evaluated using controlled attenuation parameter-transient elastography: Lesson learnt from tertiary referral center. ( 30641737 )
2019
2
Hyperuricemia and acute gout after laparoscopic sleeve gastrectomy. ( 30815983 )
2019
3
Modified Chuanhu anti-gout mixture, a traditional Chinese medicine, protects against potassium oxonate-induced hyperuricemia and renal dysfunction in mice. ( 30832523 )
2019
4
The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients. ( 30894219 )
2019
5
Associations of hyperuricemia, gout, and UA-lowering therapy with the risk of fractures: a meta-analysis of observational studies. ( 30910706 )
2019
6
Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia associated with gout. ( 30579795 )
2019
7
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey 2007-2016. ( 30618180 )
2019
8
Achievement of Target Serum Uric Acid Levels and Factors Associated with Therapeutic Failure among Japanese Men Treated for Hyperuricemia/Gout. ( 30626825 )
2019
9
Common variants in the SLC28A2 gene are associated with serum uric acid level and hyperuricemia and gout in Han Chinese. ( 30679935 )
2019
10
Hyperuricemia and gout are associated with cancer incidence and mortality: A meta-analysis based on cohort studies. ( 30693505 )
2019
11
The Daniel K. Inouye College of Pharmacy Scripts: Perspectives on the Epidemiology of Gout and Hyperuricemia. ( 30766768 )
2019
12
Atypical musculoskeletal manifestations of gout in hyperuricemia patients. ( 30799962 )
2019
13
Implications of Hyperuricemia in Severe Coronary Artery Disease. ( 30527777 )
2019
14
Prevalence and risk factors associated with hyperuricemia among working population at high altitudes: a cross-sectional study in Western China. ( 30607652 )
2019
15
Hyperuricemia is associated with acute kidney injury and all-cause mortality in hospitalized patients. ( 30644622 )
2019
16
Hyperuricemia Predicts an Early Decline in Renal Function among Older People: A Community-Based Cohort Study. ( 30700753 )
2019
17
Prognostic value of hyperuricemia in patients with acute coronary syndrome: A meta-analysis. ( 30701529 )
2019
18
Hyperuricemia predicts adverse clinical outcomes after cardiac resynchronization therapy. ( 30714413 )
2019
19
Exploration of Machine Learning for Hyperuricemia Prediction Models Based on Basic Health Checkup Tests. ( 30717373 )
2019
20
Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients. ( 30721337 )
2019
21
Inhibiting PNP for the therapy of hyperuricemia in Lesch-Nyhan disease: Preliminary in vitro studies with analogues of immucillin-G. ( 30740729 )
2019
22
Long-term prognostic impact of hyperuricemia in community. ( 30777792 )
2019
23
Asymptomatic hyperuricemia and incident stroke in elderly Chinese patients without comorbidities. ( 30787471 )
2019
24
Beneficial Effect of Dietary Fiber on Hyperuricemia in Rats and Humans: A Review. ( 30789803 )
2019
25
Association between previous schistosome infection and incident hyperuricemia: A prospective cohort study in China. ( 30789970 )
2019
26
The Prevalence of Hyperuricemia Sharply Increases from the Late Menopausal Transition Stage in Middle-Aged Women. ( 30832319 )
2019
27
Hyperuricemia is Associated with Immunoglobulin G N-Glycosylation: A Community-Based Study of Glycan Biomarkers. ( 30835642 )
2019
28
Serum Uric Acid-Lowering Effects of Combined Glycine and Tryptophan Treatments in Subjects with Mild Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. ( 30845731 )
2019
29
Hyperuricemia and its related histopathological features on renal biopsy. ( 30885171 )
2019
30
Uricase and Horseradish Peroxidase Hybrid CaHPO₄ Nanoflower Integrated with Transcutaneous Patches for Treatment of Hyperuricemia. ( 30890227 )
2019
31
Flow-mediated dilation can be used to predict incident hypertension in patients with hyperuricemia. ( 30899286 )
2019
32
Conjugated Linoleic Acid Ameliorates High fructose-induced Hyperuricemia and Renal Inflammation in Rats via NLRP3 Inflammasome and TLR4 Signaling Pathway. ( 30913372 )
2019
33
Renal impairment markers in type 2 diabetes patients with different types of hyperuricemia. ( 29635733 )
2019
34
Serum Bisphenol A is an independent risk factor of hyperuricemia: A 6-year prospective study. ( 29650240 )
2019
35
Renal Effects of Hyperuricemia. ( 29393089 )
2018
36
Identification of new drug-like compounds from millets as Xanthine oxidoreductase inhibitors for treatment of Hyperuricemia: A molecular docking and simulation study. ( 29906649 )
2018
37
Treatment of Hyperuricemia in Chronic Kidney Disease. ( 29393124 )
2018
38
Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells. ( 29393109 )
2018
39
Hypouricemic Effects of Extracts From <i>Agrocybe aegerita</i> on Hyperuricemia Mice and Virtual Prediction of Bioactives by Molecular Docking. ( 29867500 )
2018
40
Value of three-dimensional speckle tracking echocardiography to assess left ventricular function in hyperuricemia patients. ( 29790109 )
2018
41
Significance of Hyperuricemia among Community-Based Screening Participants. ( 29393126 )
2018
42
Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. ( 29790110 )
2018
43
Management of hyperuricemia and gout in obese patients undergoing bariatric surgery. ( 29888674 )
2018
44
Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia. ( 29318274 )
2018
45
Inhibiting PNP for the therapy of hyperuricemia in Lesch-Nyhan disease: preliminary in vitro studies with analogues of immucillin-G. ( 29869162 )
2018
46
Reduced peak stimulated growth hormone is associated with hyperuricemia in obese children and adolescents. ( 29785038 )
2018
47
Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. ( 29363262 )
2018
48
Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis. ( 29890945 )
2018
49
Cordycepin, a Characteristic Bioactive Constituent in<i>Cordyceps militaris</i>, Ameliorates Hyperuricemia through URAT1 in Hyperuricemic Mice. ( 29422889 )
2018
50
Dietary Potential Renal Acid Load Is Positively Associated with Serum Uric Acid and Odds of Hyperuricemia in the German Adult Population. ( 29378039 )
2018

Variations for Hyperuricemia

Expression for Hyperuricemia

Search GEO for disease gene expression data for Hyperuricemia.

Pathways for Hyperuricemia

GO Terms for Hyperuricemia

Cellular components related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.1 PFKM SLC17A1 SLC17A3 SLC22A12 SLC2A9 UMOD
2 endosome lumen GO:0031904 8.96 APOB INS

Biological processes related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.8 ABCG2 SLC17A1 SLC17A3 SLC22A12 SLC2A9
2 glucose homeostasis GO:0042593 9.61 G6PC INS PFKM
3 drug transmembrane transport GO:0006855 9.48 ABCG2 SLC17A3
4 glycogen catabolic process GO:0005980 9.37 G6PC PFKM
5 phosphate ion transport GO:0006817 9.32 SLC17A1 SLC17A3
6 sialic acid transport GO:0015739 9.26 SLC17A1 SLC17A3
7 urate transport GO:0015747 9.26 SLC17A1 SLC17A3 SLC22A12 SLC2A9
8 cholesterol efflux GO:0033344 9.16 APOB
9 glucose-6-phosphate transport GO:0015760 9.16 G6PC SLC17A3
10 urate metabolic process GO:0046415 9.1 ABCG2 G6PC SLC17A1 SLC17A3 SLC22A12 SLC2A9

Molecular functions related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.77 ABCG2 ADRB3 HPRT1 PFKM XDH
2 insulin-like growth factor receptor binding GO:0005159 9.26 INS REN
3 cholesterol transporter activity GO:0017127 9.02 APOB
4 sialic acid transmembrane transporter activity GO:0015136 8.96 SLC17A1 SLC17A3
5 drug transmembrane transporter activity GO:0015238 8.85 SLC17A3
6 urate transmembrane transporter activity GO:0015143 8.8 SLC17A3 SLC22A12 SLC2A9

Sources for Hyperuricemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....